文献速递肝肾功能剂量调整药物相互作用特殊人群用药

Capivasertib在晚期或转移性实体瘤患者中的群体药代动力学

Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours.
PubMed 文献 · Clin Pharmacokinet · 2024-08-10

本研究整合四项I/II期试验的3963份血药浓度数据,建立Capivasertib群体药代动力学模型。结果显示三室模型可充分描述其处置,清除率呈时间与剂量依赖,多数协变量无显著影响,基于模型无需预先剂量调整。

要点

  • Capivasertib 400mg bid(4/3方案)初始CL/F为62.2 L/h,约120小时后下降18%,有效半衰期8.34 h。
  • 体重、剂量、紫杉醇合用、食物效应和制剂对药代有统计学显著影响,但暴露变化<20%,无临床相关性。
  • 基于群体药代动力学,无需根据内在或外在因素进行预先剂量调整。

核心结论

  • Capivasertib药代动力学呈现中度个体间变异,大多数评估的协变量无显著影响。
  • 体重、剂量、紫杉醇合用、食物效应和制剂有统计学显著影响,但预测暴露变化<20%,不认为有临床相关性。
  • 基于群体药代动力学,无需根据内在和外在因素进行预先剂量调整。

研究设计与样本

  • 整合四项I期和II期研究的药代动力学数据,共纳入441例患者的3963份Capivasertib血浆浓度。
  • 给药剂量范围80-800 mg每日两次,采用28天或21天周期,持续给药或间歇给药方案(4天给药/3天停药或2天给药/5天停药)。
  • 评估的协变量包括剂量、方案、年龄、体重、种族、性别、肌酐清除率、肝功能、肾功能、吸烟状态、食物效应、制剂及合并用药等。

主要发现

  • 三室模型充分描述Capivasertib药代动力学,表观清除率呈中度时间和剂量依赖。
  • 多次口服400 mg每日两次(4/3方案)后,初始CL/F为62.2 L/h(个体间变异39.3%),约120小时后CL/F下降18%,有效半衰期8.34 h。
  • 从第二周起,每周第三和第四个给药日达到稳态,暴露水平可稳健抑制AKT而不抑制其他相关激酶。
  • 多次给药后,剂量80-480 mg范围内AUC和Cmax呈比例关系,超过480 mg后呈超比例关系。
  • 较低体重(47 kg vs 67 kg参考)使稳态CL/F降低12%,稳态12小时AUC和稳态Cmax增加14%。

关键数值与推荐

  • 方案、年龄、种族、性别、肌酐清除率、肝功能、肾功能、吸烟状态及与氟维司群、CYP3A诱导剂、CYP3A抑制剂或酸还原剂合用均非显著协变量。
  • 紫杉醇合用、食物效应和制剂对药代动力学有统计学显著影响,但效应较低。

临床怎么用

  • 临床使用Capivasertib时,基于群体药代动力学结果,无需根据年龄、种族、性别、肌酐清除率、肝功能、肾功能、吸烟状态或与氟维司群、CYP3A诱导剂/抑制剂、酸还原剂合用进行预先剂量调整。
  • 体重、剂量、紫杉醇合用、食物效应和制剂虽影响暴露,但变化幅度<20%,通常不具有临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Overactivation of the PI3K/AKT pathway can occur in many cancers. Capivasertib is a potent, selective pan-AKT inhibitor. The objectives of this analysis were to develop a population pharmacokinetic model for capivasertib and to quantitatively assess the impact of intrinsic and extrinsic factors on the pharmacokinetics of capivasertib. METHODS: Pharmacokinetic data from four phase I and II studies were combined. Capivasertib was administered orally at a dose range of 80-800 mg twice daily over 28-day and 21-day cycles as monotherapy or in combination with paclitaxel or fulvestrant, using continuous dosing or one of two intermittent dosing schedules: either 4 days on, 3 days off (4/3) or 2 days on, 5 days off (2/5). Several models and approaches were tested for their ability to describe capivasertib disposition. The covariates assessed included dose, schedule, age, body weight, race, sex, creatinine clearance, hepatic function, renal function, smoking status, food effect, formulation, and concomitant use with paclitaxel, fulvestrant, cytochrome P450, family 3, subfamily A (CYP3A) inducers, CYP3A inhibitors and acid-reducing agents. RESULTS: A total of 3963 capivasertib plasma concentrations from 441 patients were included. Capivasertib pharmacokinetics was adequately described by a three-compartment model where the apparent clearance (CL/F) presented a moderate time-dependent and dose-dependent clearance. Following oral administration of multiple doses of capivasertib (400 mg twice daily; [4/3]), the initial CL/F was 62.2 L/h (between-subject variability 39.3%), and after approximately 120 hours, CL/F decreased by 18%. The effective half-life was 8.34 h. Steady state was predicted to be reached on every third and fourth dosing day each week from the second week with exposure levels that produced robust inhibition of AKT but not of other related kinases. The area under the plasma concentration-time curve and maximum plasma concentration of capivasertib were proportional between the dose levels of 80-480 mg after multiple doses but more than proportional beyond 480 mg. Schedule, age, race, sex, creatinine clearance, hepatic function, renal function, smoking status and concomitant use with fulvestrant, CYP3A inducers, CYP3A inhibitors or acid-reducing agents were not significant covariates for capivasertib pharmacokinetics. Concomitant use of paclitaxel, food effect and formulation statistically significantly affected capivasertib pharmacokinetics, but the effect was low. Body weight was statistically significantly related to capivasertib CL/F, with a 12% reduction in CL/F at steady state and a 14% increase in the area under the curve for 12 hours at steady state and maximum concentration at steady state at a lower body weight (47 kg vs 67 kg reference). CONCLUSIONS: Capivasertib pharmacokinetics showed moderate between-subject variability, and most covariates assessed had no significant impact. Body weight, dose, concomitant use of paclitaxel, food effect and formulation showed statistically significant effects. However, these were predicted to impact exposure to capivasertib by <20% and were not expected to be clinically relevant. Based on the population pharmacokinetics, no a priori dose adjustment is needed for intrinsic and extrinsic factors.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Fernandez-Teruel C, Cullberg M, Eberlein C, et al. Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. Clin Pharmacokinet. 2024. PMID: 39127854. doi:10.1007/s40262-024-01407-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。